1. Renal function and venous thromboembolic diseases.
- Author
-
Janus N, Mahé I, Launay-Vacher V, Laroche JP, and Deray G
- Subjects
- Anticoagulants pharmacokinetics, Anticoagulants therapeutic use, Cardiovascular Diseases, Drug Overdose prevention & control, Heparin administration & dosage, Heparin adverse effects, Heparin therapeutic use, Heparin, Low-Molecular-Weight therapeutic use, Humans, Pulmonary Embolism, Renal Insufficiency, Chronic complications, Renal Insufficiency, Chronic physiopathology, Risk Factors, Venous Thromboembolism complications, Vitamin K antagonists & inhibitors, Anticoagulants adverse effects, Kidney physiopathology, Venous Thromboembolism drug therapy, Venous Thromboembolism physiopathology
- Abstract
Anticoagulant agents have been approved by international regulatory agencies to prevent and treat venous thromboembolism (VTE). However, chronic kidney disease (CKD) is: (1) highly frequent in VTE patients; (2) strongly linked to VTE; and (3) a risk factor for cardiovascular morbidity/mortality and fatal pulmonary embolism. Therefore, an increasing number of patients are presented with CKD and VTE and more and more physicians must face the questions of the management of these patients and that of the handling of anticoagulant agents in CKD patients because of the pharmacokinetic modifications of these drugs in this population. These modifications may lead to overdosage and dose-related side effects, such as bleeding. It is therefore necessary to screen VTE patients for CKD and to modify the doses of anticoagulants, if necessary., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF